JNJ vs TOI

Johnson & Johnson (JNJ) continues to demonstrate robust financial performance, with Q1 2026 results exceeding consensus on both revenue and adjusted EPS, reflecting nearly 10% YoY revenue growth. Its diversified healthcare portfolio provides significant market leadership and a wide economic moat, indicating stability and consistent profitability. However, its massive market capitalization of $555....

Score Change Explanation: The increase from 18/100 to 29/100 is primarily driven by the reported Q1 2026 earnings, where TOI significantly beat both revenue and EPS consensus estimates ($147.44M vs $142.10M, and -$0.02 vs -$0.07). This positive earnings surprise, along along with the provision of updated FY2026 revenue guidance ($630M-$650M) and a material open-market purchase by a 10% owner (Cher...